638 related articles for article (PubMed ID: 29581249)
1. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against cisplatin-induced acute kidney injury.
Yang Y; Yu X; Zhang Y; Ding G; Zhu C; Huang S; Jia Z; Zhang A
Clin Sci (Lond); 2018 Apr; 132(7):825-838. PubMed ID: 29581249
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.
Miao AF; Liang JX; Yao L; Han JL; Zhou LJ
Ren Fail; 2021 Dec; 43(1):803-810. PubMed ID: 33966598
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) alleviates sepsis-induced acute lung injury.
Han F; Wu G; Han S; Li Z; Jia Y; Bai L; Li X; Wang K; Yang F; Zhang J; Wang X; Guan H; Linlin S; Han J; Hu D
Respir Physiol Neurobiol; 2020 Oct; 281():103506. PubMed ID: 32726645
[TBL] [Abstract][Full Text] [Related]
4. Nonclinical Characterization of the Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat, a Novel Treatment of Anemia of Chronic Kidney Disease.
Del Balzo U; Signore PE; Walkinshaw G; Seeley TW; Brenner MC; Wang Q; Guo G; Arend MP; Flippin LA; Chow FA; Gervasi DC; Kjaergaard CH; Langsetmo I; Guenzler V; Liu DY; Klaus SJ; Lin A; Neff TB
J Pharmacol Exp Ther; 2020 Aug; 374(2):342-353. PubMed ID: 32487538
[TBL] [Abstract][Full Text] [Related]
5. Pretreatment with Roxadustat (FG-4592) Attenuates Folic Acid-Induced Kidney Injury through Antiferroptosis via Akt/GSK-3
Li X; Zou Y; Xing J; Fu YY; Wang KY; Wan PZ; Zhai XY
Oxid Med Cell Longev; 2020; 2020():6286984. PubMed ID: 32051732
[TBL] [Abstract][Full Text] [Related]
6. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.
Bernhardt WM; Câmpean V; Kany S; Jürgensen JS; Weidemann A; Warnecke C; Arend M; Klaus S; Günzler V; Amann K; Willam C; Wiesener MS; Eckardt KU
J Am Soc Nephrol; 2006 Jul; 17(7):1970-8. PubMed ID: 16762988
[TBL] [Abstract][Full Text] [Related]
7. Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China.
Chen N; Qian J; Chen J; Yu X; Mei C; Hao C; Jiang G; Lin H; Zhang X; Zuo L; He Q; Fu P; Li X; Ni D; Hemmerich S; Liu C; Szczech L; Besarab A; Neff TB; Peony Yu KH; Valone FH
Nephrol Dial Transplant; 2017 Aug; 32(8):1373-1386. PubMed ID: 28371815
[TBL] [Abstract][Full Text] [Related]
8. Roxadustat (FG-4592) protects against ischaemia/reperfusion-induced acute kidney injury through inhibiting the mitochondrial damage pathway in mice.
Zhang M; Dong R; Yuan J; Da J; Zha Y; Long Y
Clin Exp Pharmacol Physiol; 2022 Feb; 49(2):311-318. PubMed ID: 34653291
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2.
Yang Y; Liu S; Gao H; Wang P; Zhang Y; Zhang A; Jia Z; Huang S
Free Radic Biol Med; 2020 May; 152():821-837. PubMed ID: 32004633
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Carcinogenic Potential of Roxadustat (FG-4592), a Small Molecule Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase in CD-1 Mice and Sprague Dawley Rats.
Beck J; Henschel C; Chou J; Lin A; Del Balzo U
Int J Toxicol; 2017; 36(6):427-439. PubMed ID: 29153032
[TBL] [Abstract][Full Text] [Related]
11. Roxadustat attenuates experimental pulmonary fibrosis in vitro and in vivo.
Huang H; Wang X; Zhang X; Wang H; Jiang W
Toxicol Lett; 2020 Oct; 331():112-121. PubMed ID: 32534005
[TBL] [Abstract][Full Text] [Related]
12. FG-4592 Accelerates Cutaneous Wound Healing by Epidermal Stem Cell Activation via HIF-1α Stabilization.
Tang D; Zhang J; Yan T; Wei J; Jiang X; Zhang D; Zhang Q; Jia J; Huang Y
Cell Physiol Biochem; 2018; 46(6):2460-2470. PubMed ID: 29742498
[TBL] [Abstract][Full Text] [Related]
13. Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS.
Yu J; Wang S; Shi W; Zhou W; Niu Y; Huang S; Zhang Y; Zhang A; Jia Z
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403364
[TBL] [Abstract][Full Text] [Related]
14. HIF activation protects from acute kidney injury.
Weidemann A; Bernhardt WM; Klanke B; Daniel C; Buchholz B; Câmpean V; Amann K; Warnecke C; Wiesener MS; Eckardt KU; Willam C
J Am Soc Nephrol; 2008 Mar; 19(3):486-94. PubMed ID: 18256363
[TBL] [Abstract][Full Text] [Related]
15. Evidence for the Capability of Roxadustat (FG-4592), an Oral HIF Prolyl-Hydroxylase Inhibitor, to Perturb Membrane Ionic Currents: An Unidentified yet Important Action.
Chang WT; Lo YC; Gao ZH; Wu SN
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31795416
[TBL] [Abstract][Full Text] [Related]
16. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.
Besarab A; Provenzano R; Hertel J; Zabaneh R; Klaus SJ; Lee T; Leong R; Hemmerich S; Yu KH; Neff TB
Nephrol Dial Transplant; 2015 Oct; 30(10):1665-73. PubMed ID: 26238121
[TBL] [Abstract][Full Text] [Related]
17. Stabilizing HIF to Ameliorate Anemia.
Voit RA; Sankaran VG
Cell; 2020 Jan; 180(1):6. PubMed ID: 31951520
[TBL] [Abstract][Full Text] [Related]
18. Preischemic targeting of HIF prolyl hydroxylation inhibits fibrosis associated with acute kidney injury.
Kapitsinou PP; Jaffe J; Michael M; Swan CE; Duffy KJ; Erickson-Miller CL; Haase VH
Am J Physiol Renal Physiol; 2012 May; 302(9):F1172-9. PubMed ID: 22262480
[TBL] [Abstract][Full Text] [Related]
19. Roxadustat (FG-4592) protects against ischaemia-induced acute kidney injury via improving CD73 and decreasing AIM2 inflammasome activation.
Yang H; Wu Y; Cheng M; Zhang M; Qiu X; Liu S; Zhang M
Nephrol Dial Transplant; 2023 Mar; 38(4):858-875. PubMed ID: 36413468
[TBL] [Abstract][Full Text] [Related]
20. Stabilization of HIF-1α by FG-4592 promotes functional recovery and neural protection in experimental spinal cord injury.
Wu K; Zhou K; Wang Y; Zhou Y; Tian N; Wu Y; Chen D; Zhang D; Wang X; Xu H; Zhang X
Brain Res; 2016 Feb; 1632():19-26. PubMed ID: 26707978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
